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Introduction
Each year an estimated 7-million people in the USA need
composite tissue reconstruction because of surgical exci-
sion of tumors, accidents and congenital malformations
[1]. Limb amputees alone comprise over 1.2 million of
these. This figure is more than double the number of
solid organs needed for transplantation [1]. The concept
of composite tissue allotransplantation (CTA) is not new.
As far back as the fourth century twin brothers Saints
Cosmos and Damian were said to have replaced the dis-
eased limb of a sleeping man with that of a recently
deceased moor [2]. Centuries later in 1963, a hand trans-
plant was attempted in Ecuador [3], but was rejected after
only 3 weeks [4]. The development of more efficacious
immunotherapy in the 1980s moved the possibility of
successful CTA closer to reality. The truly modern era of
CTA dawned in 1998, when an international team per-
formed a successful hand transplant in Lyon, France. To
date, 24 hand transplants and two face transplants have
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Summary
Each year an estimated 7-million people in the USA need composite tissue
reconstruction because of surgical excision of tumors, accidents and congenital
malformations. Limb amputees alone comprise over 1.2 million of these. This
figure is more than double the number of solid organs needed for transplanta-
tion. Composite tissue allotransplantation in the form of hand and facial tissue
transplantation are now a clinical reality. The discovery, in the late 1990s, that
the same immunotherapy used routinely in kidney transplantation was also
effective in preventing skin rejection made this possible. While these new treat-
ments seem like major advancements most of the surgical, immunological and
ethical methods used are not new at all and have been around and routinely
used in clinical practice for some time. In this review of composite tissue allo-
transplantation, we: (i) outline the limitations of conventional reconstructive
methods for treating severe facial disfigurement, (ii) review the history of com-
posite tissue allotransplantation, (iii) discuss the chronological scientific advan-
ces that have made it possible, (iv) focus on the two unique clinical scenarios
of hand and face transplantation, and (v) reflect on the critical issues that must
be addressed as we move this new frontier toward becoming a treatment in
mainstream medicine.
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been performed (Table 1). These breakthroughs have cap-
tured the public’s imagination, and stimulated a great
deal of discussion in the lay and scientific communities.
Historically, transplant and reconstructive surgeons
have enjoyed a close relationship having worked hand in
hand advancing their respective fields. The publicity and
reaction to the recent hand and face transplants are remi-
niscent of the first cardiac transplant performed in 1967
by Christian Barnard in South Africa. Although the con-
sensus of the medical community at the time was that the
world was not ready, this procedure undoubtedly ener-
gized many centers throughout the world and accelerated
successful outcomes.
In this manuscript we: (i) outline the limitations of
conventional reconstructive methods for treating severe
facial disfigurement, (ii) review the history of composite
tissue allotransplantation, (iii) discuss the chronological
scientific advances that have made it possible, (iv) focus
on the two unique clinical scenarios of hand and face
transplantation, and (v) reflect on the critical issues that
must be addressed as we move this new frontier toward
becoming a treatment in mainstream medicine.
Limitations of conventional reconstructive surgery
Conventional reconstructive treatments include (i) reat-
taching amputated body parts using microsurgical tech-
niques, (ii) transferring adjacent or distant autologous
tissues to reconstruct tissue defects and (iii) using pros-
thetic materials to hide or disguise the tissue defect.
Over the years advances in these conventional treat-
ments have greatly improved the surgeon’s ability to
cover large tissue defects and to a large extent even
restore form and function. Of the conventional methods
listed above the first provides, by far, the best aesthetic
and functional outcomes due to the fact that the defect is
reconstructed using the original tissue. However, this
option is often not possible because the tissue in question
was destroyed beyond use (burns, cancer extirpation) or
because the tissue did not exist in the first place (congen-
ital birth defects). While the later two treatments (autolo-
gous tissues and prosthetics) do a good job of covering
large wounds they are associated with several shortcom-
ings including technical failure, infection, rejection of the
prosthetic materials, and poor functional return and cos-
mesis. In addition conventional treatments often require
multiple follow-up revision surgeries and prolonged reha-
bilitation, which impede patients from returning to work
and normal life. All of these factors place a tremendous
negative impact on patients who suffer with these
deformities, their family upon whom the burden of care
and dependency often falls and ultimately our healthcare
system and society that must absorb the financial cost of
multiple procedures, prolonged hospitalization, and loss
of work productivity. Composite tissue allotransplantation
(CTA), in the form of hand and face transplantation
could eliminate many of these complications and draw-
backs and provide superior functional and aesthetic out-
comes and in doing so would revolutionize the field of
reconstructive surgery [5].
The history of composite tissue allotransplantation
Long before solid organ transplantation was considered,
‘The legend of the black leg’ (Leggenda Aurea) recounted
the tale of twin brothers Cosmas and Damian who
replaced the diseased leg of a sleeping man with that of a
recently deceased Ethiopian Moor in 348 ad [2]. This
legend has been immortalized in several paintings by a
number of 15th century artists [6]. In the 16th century,
in Bologna Italy, Gaspare Tagliacozzi, (1547–1599), con-
sidered by many to be the father of modern Plastic Sur-
gery, described transplantation of the nose from a slave to
his master. Interestingly, the reported death of the slave
3 years later, corresponded to failure of the transplant
[7]. Subsequently, several reports of tissue transplants
appeared periodically in the literature. The first substan-
tiated successful allotransplant was that of sheepskin
reported by Bunger in 1804 [8]. In the early 1900s Carrel
described successful orthotopic hind limb transplants in
dogs [9]. Subsequently, Alexis Carrel described connecting
an artery from the arm of a father to the leg of his infant
son in order to treat intestinal bleeding. Although this
experiment was a success, the discovery of anticoagulants
soon made such direct transfer unnecessary. For his pion-
eering efforts, Carrel won the Nobel Prize in 1912 [10].
Around the same time Guthrie described heterotopic allo-
transplantation of dog heads onto the neck of recipient
dogs. Restoration of salivation and eyelid function in the
transplanted heads was reported postoperatively [11].
Although these studies laid the foundation for the devel-
opment of the surgical techniques (microvascular nerve
and vessel repair) necessary to transplant tissues and
organs, the immunological barriers were yet to be
addressed.
The tragedies of war provided the impetus for begin-
ning to study the immunological barriers associated with
tissue allotransplantation. A large number of severely
burned fighter pilots in the Battle of Britain in World
War II were the catalyst for the formation of a burns unit
at the Glasgow Royal Infirmary. The appointment of a
young Plastic Surgeon, Thomas Gibson and a Zoologist,
Peter Medawar allowed several early advances. While car-
ing for these patients Gibson noted that those who
received skin grafts transplanted from another individual
demonstrated accelerated rejection following a second
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skin graft from the same donor at a later date [10]. At
the same time Medawar demonstrated that specific char-
acteristics of the rejection process, such as latency, mem-
ory, and specificity of graft destruction, were the
consequence of an active immune response mounted by
the recipient [10]. These discoveries laid the groundwork
for the development of the field of modern transplant
immunology and earned Medawar the Nobel Prize in
1960. In the 1950s, Joseph Murray, a Plastic Surgeon,
studied skin and kidney transplants in dogs and later
went on to perform the first successful human kidney
transplant between identical twins [12]. This landmark
procedure sparked new interest in the field and led to
many advances in solid organ transplantation. In 1990,
Murray was awarded the Nobel Prize in Physiology/Medi-
cine for his pioneering work in organ transplantation.
The late 1950s and early 1960s brought the discovery
of several immunosuppressive agents such as azathiop-
rine, 6-mercaptopurine and corticosteroids [13–16].
While in animal experiments these agents prolonged graft
survival the dosages necessary to do so in CTA were toxic
and often fatal. In 1963, a team of surgeons in Ecuador
performed the first human hand transplant (Table 1).
The immunosuppression used [azathioprine (AZA) and
hydrocortisone] at the time was inadequate and the hand
rejected within 3 weeks and was amputated [3,4].
In 1976, the introduction of cyclosporin A [17] ushered
in a new era of transplantation. Animal studies followed
by human studies using cyclosporin A in heart, kidney,
pancreas and liver transplantation [18,19] demonstrated
effective immunosuppression. These positive experiences
in organ transplants led to several reports of small animal
experiments in which CTAs in the form of hind limb and
mandible bone transplants were performed and prolonged
allograft survival was demonstrated [20–30]. In the late
1970s and early 1980s, three separate groups tested the
efficacy of cyclosporin A in upper extremity transplants
in primates [31–33]. Although rejection was suppressed
for periods of up to 300 days, in these experiments the
highly immunogenic skin portions of transplanted
extremities were rejected within the first few months after
transplantation. These discouraging results together with
the failed human hand transplant in Ecuador caused re-
constructive surgeons to abandon further attempts to
transplant hands for another decade.
In the early 1990s, cyclosporin-AZA steroid-based regi-
mens were used in a series of clinical CTAs to reconstruct
nerves [34–37], tendons [38], muscle [39], bone and joint
[40], and laryngeal defects [41]. In addition to the above
listed procedures, more recently, additional CTAs have
been reported in the clinical setting to reconstruct
abdominal wall muscle [42], tongue [43,44; http://
www.newscientist.com/article.ns?id¼dn3964] and uterusS
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[45]. While the outcomes in these attempts have been
reported to be generally positive, none of these CTAs
contained skin and the associated appendages.
Human hand transplantation
In September of 1991, a conference on the clinical use of
CTA was held in conjunction with the Rehabilitation
Research and Development Service of the Department of
the Veterans Affairs in Washington, DC. The purpose of
the conference was to determine ‘the clinical feasibility
of transplanting limbs in patients with limb loss’ and ‘the
direction in which clinically oriented limb transplantation
research should head’. The conference participants con-
cluded that CTA would be clinically possible in the near
future and that ‘historic’ initial trials would occur over
the next 2–5 years [46].
This prediction did not come to pass and 6 years later in
November 1997 the 1st International Symposium on CTA
was held in Louisville, Kentucky to discuss ‘the barriers
standing in the way of performing human hand trans-
plants’. The meeting brought together leading experts in
the fields of reconstructive surgery, transplant immuno-
logy, and medical ethics. The 2 days of discussions focused
primarily on immunological and ethical barriers and while
many opinions were aired, the overall consensus of those
present at the meeting was that sufficient research had been
done and the time had come to move hand transplantation
research into the clinical arena. This was summed up in
the closing remarks of the symposium’s proceedings that
concluded ‘…it is time to Just Do It’ [47].
At the time of the 1997 CTA symposium in Louisville,
the Plastic Surgery Research Laboratories at the University
of Louisville hosting the meeting was actively engaged in
animal research pursuing a variety of approaches focused
on maximizing immunosuppression (because of the high
immunogenicity of the skin) and minimizing their toxic
side effects (because of the reluctance of hand surgeons to
expose their amputee patients to the risks of immunosup-
pression). In keeping with these criteria several novel
methods of local immunosuppressive drug delivery were
explored. These included topical drug applications [48],
direct drug delivery using implanted pumps [48–52] and
magnetic drug targeting (attaching drugs to metal parti-
cles, infusing them systemically and then using a magnet
placed over the transplanted allograft to localize the drug)
[53,54]. Additional approaches that met the criteria of
maximal immunosuppression with minimal toxicity were
also studied; tolerance induction [55–58], low-dose
immunosuppression [59] and lymph node removal [60,61].
In one of these experiments investigating local drug
delivery using implanted pumps in a pig forelimb CTA
model [62,63] the control group consisted of animals
receiving a drug regimen, considered at the time, and still
today, to be the gold standard in clinical kidney trans-
plantation (tacrolimus/MMF/corticosteroid). Unexpect-
edly, the pumps (experimental group) malfunctioned,
while the drug combination, (tacrolimus/MMF/cortico-
steroid), administered to the control animals effectively
suppressed CTA ‘skin’ rejection for the duration of the
experiment with relatively low toxicity. Based on these
findings the University of Louisville team immediately
applied to the hospitals’ institutional review board for
approval to perform 10 human hand transplants and at
the same time presented their findings at an international
hand surgery meeting in Vancouver [64]. These findings
were subsequently published in a landmark paper [65].
Based on these findings, between 1998 and 1999, teams
in Lyon (France) [66], Louisville (USA) [67] and Guang-
zhou (China) performed the first successful human hand
transplants using tacrolimus/MMF/corticosteroid combi-
nation therapy [68]. At the time this manuscript was
written, 24 hands (six double hand transplants and 12
single hand transplants) had been transplanted in 18 indi-
viduals world-wide. Seven of these are >7 years post
transplant and only two graft failures have been reported,
one due to noncompliance [69] and the other performed
in China, because of unclear etiology [70].
Functional recovery
Overall the functional outcomes and patient satisfaction
have been reported to be good [68,70] (Table 1). In all
patients arterial blood supply and venous outflow have
been reported to be satisfactory in the early post-trans-
plant period and subsequently hands presented normal
skin color and texture, and normal hair and nail growth.
Recovery of sensibility has been documented in all
transplanted hands. The grade of sensory return paralleled
results found in autologous replantation after trauma. In
particular, protective sensation was achieved in all patients
within 6–12 months and, as time progressed, 88% showed
onset of more subtle discriminative sensation.
Recovery of motor function enabled the patients to
perform most daily activities, including eating, driving,
grasping objects, riding a bicycle or a motorbike, shaving,
using the telephone, and writing. At 2 years all patients
had returned to work, and improved manual skills
allowed them not only to resume their previous jobs but
also, in some cases, to find more suitable employment.
This contributed to a reported improvement in quality of
life in 83% of cases [68,70].
In spite of these promising early outcomes in this relat-
ively small number of patients, debate continues over
whether the risks associated with the immunosuppression
drugs, required to prevent rejection are worth the benefits
of hand transplantation. These risks are well known,
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having been extensively studied in large populations of
solid organ transplant recipients and more recently in the
limited number of hand transplant recipients. Below we
summarize the immunosuppression related risks reported
in the hand transplant population.
Acute rejection
While it is not possible to predict long-term rejection
in hand transplantation one can draw some conclusions
from preliminary findings in the relatively small number
of human hand transplants performed since 1998. At
1 year post-transplant, acute rejection rates have been
reported to be 65% (excluding one transplant between
identical twins), 11 of 17 allotransplants experienced a
total of 26 rejection episodes) with tacrolimus/MMF/
corticosteroid therapy [70]. In spite of this relatively
high incidence of acute rejection all episodes were
reported to have been successfully reversed and allograft
and patient survival were 100% at 2 years post-trans-
plantation. At a mean of 43 months, graft and patient
survival were 89% and 100% respectively. As aforemen-
tioned, the two graft failures were reported to be due
to noncompliance [69] with the reason for the other
failure unclear [70].
These higher acute rejection rates in hand transplant
recipients compared to kidney recipients receiving tacroli-
mus/MMF/corticosteroid therapy, are likely a result of the
greater immunogenicity of the skin and its appendages
[69,71–73] while the high allograft survival rates (despite
relatively high acute rejection rates) may be due to
increased diagnostic sensitivity and early recognition of
(sub) acute rejection by visual skin inspection. The
importance of early diagnosis of acute rejection has been
demonstrated in clinical kidney transplantation. Current
methods of monitoring acute rejection are relatively
insensitive, resulting in delayed anti-rejection treatment
and decreased long-term allograft survival. The signifi-
cance of early diagnosis and treatment of acute rejection
has been demonstrated in prospective studies of renal
allograft biopsies [74] where unrecognized acute rejection
was associated with an increased risk of chronic allograft
nephropathy and late graft loss [75,76]. In contrast to
solid organ transplants, acute rejection in hand trans-
plants is manifested by early, visually apparent cutaneous
changes that have a high correlation with histopathologic
findings. Skin biopsies from co-transplanted ‘distant sen-
tinel skin flaps’ can provide valuable adjunctive informa-
tion regarding acute rejection with minimal patient
morbidity [71,73].
Chronic rejection
While the exact mechanisms of chronic rejection have not
been defined, both immunologic and non-immunologic
factors have been implicated [55]. Experience from kidney
transplantation has shown that (sub) acute rejection
negatively affects renal allograft function [52,58,59] and
survival [60,61]. However, in hand transplantation, this
connection between subacute and chronic rejection has
not yet been established.
In a single case clinical and histologic characterization
of what was believed to be chronic (cutaneous) rejection
was reported in the first human hand transplant recipient
at the time his hand was surgically removed because of
noncompliance. Examination of the rejected allograft
demonstrated a histologic picture identical to chronic
lichenoid GVHD [71,77].
In the other 16 hand transplant recipients chronic
rejection has not been reported at a median follow-up of
43 months.
This low incidence of chronic rejection, even with con-
comitant high acute rejection rates [70] suggests that
chronic rejection may not be as important a threat in
hand as it is in renal transplantation [78,79]. Neverthe-
less, longer term follow-up and additional evaluations of
chronic rejection in human hand and other CTAs are
needed to better define its risk and influence on long
term allograft function and survival.
Complications of immunosuppression
The primary complication associated with immunosup-
pressive therapy in the hand transplant population so far
is infection. Complications such as malignancies, cardio-
vascular related disease, nephrotoxicity, gastrointestinal
adverse effects and diabetes have not been reported [70].
Of the infections reported in hand transplant recipients,
bacterial infection occurred at a rate of 12% (two infec-
tions: Clostridium difficile enteritis and Staphylococcus
aureus osteitis), Fungal infections occurred in 28% (all
cutaneous mycoses without invasive disease) and viral
infection in 34% of cases. Only 6% of patients experi-
enced cutaneous herpes simplex infections. None of these
infections resulted in graft or patient loss [70]. Post-
transplantation bone disease was reported in a single case
of avascular necrosis of the hip. While post transplant
diabetes mellitus has not been reported in hand trans-
plant recipients, transient hyperglycemia occurred in 50%
of the patients, primarily while receiving high corticoster-
oid doses early after transplantation [68,70]. Noncompli-
ance was a problem in one of 18 patients and this could
possibly have been avoided had a more careful pre-trans-
plant psychosocial screening assessment been performed.
In conclusion, overall, with a post- transplant follow-
up of 7 years in human hand transplantation the inci-
dence of graft failure and complications has been low
while functional and aesthetic recovery has been described
as good.
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Human face transplantation
To date, three cases of head and neck allotransplantation
have been reported, two in China [80,81] and one in
France [82,83] (Table 1). Facial transplantation has cap-
tured the interest and imagination of the media, scien-
tists, and the lay public. Our face is much more than the
anatomical location where our olfactory, auditory and
visual organs are situated. We use facial expressions to
communicate with the world around us and our face is
the window through which others see and come to know
us. It is this great importance we attach to our face that
makes facial disfigurement such a devastating condition.
Perception of the face dominates peoples’ views of disfig-
ured individuals and their facial appearance becomes their
defining feature. Stevenage and McKay found in their
research that job recruiters had a negative perception of
facially disfigured applicants, which was associated with
an adverse bias of work-related skills [84]. Facially disfig-
ured individuals are frequently shut-ins, hiding from
social relationships that others take for granted. They face
a number of psychological and social problems, such as
social anxiety, lowered self-confidence and self-esteem,
negative self-image, depression, alcohol abuse, and marital
problems [85–88]. Of all the physical handicaps, none is
as socially devastating as facial disfigurement. In a large
number of cases, facial disfigurement leads to depression,
social isolation, and increased risk of suicide [85,89].
The positive early outcomes in human hand transplants
encouraged and stimulated the team at the University of
Louisville to apply their research and clinical experience
to developing a program to perform human face trans-
plants. The fact that the drug combination tacrolimus/
MMF/corticosteroid effectively suppressed skin rejection
both in their preclinical animal studies [64,65] and more
importantly in their own [67] as well as other team’s
human hand transplants [68] meant that another major
barrier to performing face transplants had been lowered.
The research team consulted with head and neck
reconstructive surgeons, asking them what they felt was
the greatest barrier standing in the way of performing
facial transplantation; and they responded ‘ethical and
psychosocial issues’ ‘specifically those related to risk
versus benefit’.
Based on this, the University of Louisville team shifted
its research focus from investigating methods of suppres-
sing CTA ‘skin’ rejection to defining the ethical parame-
ters necessary to perform human face transplantation. To
this end, they developed a strong multidisciplinary team
including respected scientists and clinicians in the fields
of psychology (body image), psychiatry, bioethics, soci-
ology and plastic, head and neck, ophthalmologic and
transplant surgery. Together they developed a set of
ethical guidelines to guide their efforts and a research
strategy to investigate risk versus benefit issues in CTA.
The first suggestion to the public that face transplanta-
tion was actually being considered as a clinical possibility
stemmed from a presentation made by Mr Peter Butler, a
consultant plastic surgeon at London’s Royal Free Hospi-
tal in the UK, at the December 2002 meeting of the Brit-
ish Association of Plastic Surgeons [90]. He asserted that
ten patients had approached him requesting facial trans-
plants over the last year. Members of the media were in
attendance, reporting on the event, and began to specu-
late that face transplant was indeed a clinical reality and
this sparked media frenzy. This frenzy reached its height
in Britain in December 2002 when the media singled out
a young lady with facial disfigurement and reported that
she had been selected by Mr Butler as the first face trans-
plant recipient [91,92]. In response to this circus like
atmosphere, James Partrige, the CEO of the well recog-
nized support organization for facially disfigured ‘Let’s
Face it’, and a victim of facial disfigurement himself,
called upon the Royal College of Surgeons (RCS) to ‘cre-
ate a moratorium on further media coverage of the issue’
[44]. The RCS formed a ‘Working Party on face trans-
plantation’ consisting of experts in the fields of Ethics,
Reconstructive Surgery, Psychology and Transplantation
to assess the current scientific merits of face transplanta-
tion.
On November 19th 2003, at the London Museum, at a
much publicized ‘Public Debate on the Feasibility of Face
Transplantation’ [93], Sir Peter Morris, the head of the
RCS and chair of the Working Party recommended
‘…that until there is further research and the prospect of
better control of complications it would be unwise to pro-
ceed with human facial transplantation’. The report ended
welcoming comments in reponse to these findings [44].
In response to the RCS report, the University of Louis-
ville team, who were also present and presented at the
Public Debate at the London Museum, published their
position [94]. Based on their own immunological and risk
versus benefit research as well their experience in hand
transplantation and the experience and research of others
they concluded that the major technical, immunological
and ethical barriers standing in the way of performing
human facial transplantation had been overcome: and
that ‘in a select population of severely disfigured individ-
uals facial transplantation, despite its recognized risks,
could provide a better treatment option than current
methods’ and thus ‘should move into its clinical research
phase’ [94]. Immediately following this, the same team in
Louisville published their ethical guidelines for perform-
ing facial transplantation in the American Journal of Bio-
ethics [94]. A key component of this set of ethical
guidelines is ‘Open Display and Public and Professional
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Discussion and Evaluation’. To achieve this, the above
cited publication invited experts from several related
fields, including the surgical teams in the UK, France and
at the Cleveland Clinic in the US to submit written com-
mentaries critiquing these ethical guidelines. Fifteen com-
mentaries [86,95–108] were published alongside the
Louisville teams’ ethical guidelines and their response to
the commentaries [109]. Additional steps taken to pro-
mote ‘Open Display and Public and Professional Discus-
sion and Evaluation’ included other scientific publications
[47,110–112] and presentations to both scientific [102]
and public audiences [93] as well as organizing forums
for scientific discussion [113,114].
In keeping with their practice of ‘Open Display and
Public and Professional Discussion and Evaluation’ in all
of these forums, the University of Louisville team pre-
sented and discussed their position and more import-
antly listened to and learned from the positions of
others. In this exercise of open discussion it became
immediately apparent that the critics of face transplanta-
tion based their positions largely on theoretical discus-
sions and their subjective opinions about the risk and
benefits of this procedure. None of the vocal critics had
actually referred to the direct life experiences of those
confronting the risks of immunosuppression or had col-
lected data from individuals who might benefit from dif-
ferent types of transplants. In contrast, the University of
Louisville team expanded the risk versus benefit research
they had begun with hand transplantation [115] to ques-
tions relevant to face transplantation. They developed
and validated [116] a questionnaire-based instrument
(Louisville Instrument for Transplantation; LIFT) to
assess the amount of risk individuals would be willing to
accept to receive different types of nonlife-saving trans-
plant procedures (foot, single and double hand, larynx,
hemi- and full face CTAs and kidney transplants). Using
the LIFT, they questioned over 300 individuals with real
life experiences in the risks of immunosuppression (kid-
ney transplant recipients) [117] and individuals who
could benefit from one of these procedures; limb ampu-
tees [118], laryngectomee patients [119] and individuals
who had suffered facial disfigurement [120]. Of all those
questioned in this series of studies, regardless of their
individual life experience, all would risk the most to
receive a face transplant. Of particular interest was the
fact that they would risk even more to receive a face
than a kidney transplant, which is considered standard
care and for which there is no risk versus benefit debate.
It was based on these findings that University of Louis-
ville team took the position that the ethical barriers
based on risk versus benefit had been lowered and the
time had come to move facial transplantation research
into the clinical arena [4,94].
In 2004, in preparation to perform clinical face trans-
plants, a team in Paris France, led by Professor Laurent
Lantieri submitted a proposal to the French government’s
advisory council on bioethics (Comit’e Consultatif
National d’Ethique; CCNE). The council responded in a
report entitled ‘Composite tissue allotransplantation
(CTA) of the face; full or partial facial transplant’. The
report concluded that while it was not ‘ethical’ to per-
form a full face transplant at the time a partial face trans-
plant (a triangle-shaped part of the face including the
nose and mouth) could be performed [42].
Later, in October, 2005 an institutional review board at
the Cleveland Clinic in Cleveland USA, approved a pro-
posal submitted by a team at their hospital, led by
Dr Maria Siemionow, to proceed with human face trans-
plants [121] at which time the team began to screen
potential patients. Also in 2005, in the US the American
Society for Plastic Surgery (ASPS) and the American Soci-
ety of Reconstructive Microsurgery (ASRM) issued their
‘guiding principles’ recommending ‘that due to the
unknown risks and benefits, those involved in this
important work move forward in incremental steps’
[122,123].
In September 2003 a team of surgeons at the Jinling
Hospital in Nanjing, China transplanted a skin flap that
included a large portion of posterior scalp and both ears
from a donor onto a 72-year-old woman following the
removal of a large cutaneous malignant melanoma (Table 1)
[80]. While this transplant went relatively unnoticed by
the scientific, medical and lay communities, many of the
surgical, immunological and ethical issues and concerns
of this procedure are present in facial transplantation and
a great deal could be learned from following the out-
comes in this patient. In November, 2005, in Amiens,
France a surgical team led by Dr Bernard Devauchelle
and Jean-Michel Dubernard announced that they had
performed a partial face transplant on a 38-year-old
female, whose face has been disfigured by a dog bite
(Table 1). The surgery involved transplanting a triangular
graft of tissue extending from the nose to the chin inclu-
ding the lips. ‘Initial reports indicate that the recipient is
doing well and both the medical community and the lay
public have reacted favorably to the procedure’ [82,83].
While it is too early to assess the functional outcome
in this patient, early reports indicate that there is some
return of movement and sensation. If this is true this
mimics what has happened in the hand transplants where
return of function was better than expected [68,70]. This
effect is thought to be due to a collateral effect of accel-
erating nerve regeneration provided by the primary anti-
rejection drug, tacrolimus, being used in these recipients
[34]. While the anticipated functional recovery is not
100%, it is expected to be superior to that achieved with
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conventional reconstructive methods (skin grafts, trans-
planted autologous tissues and facial prosthetics) in the
population of patients being considered [109]. Immedi-
ately following this first clinical case, an ethics commit-
tees in the UK granted permission to Peter Butler at the
Royal Free Hospital in London to perform facial trans-
plants [121].
In April 2006 a team in Xi’an, capital of Shaanxi Prov-
ince in northwest China, performed a face transplant on
a 30-year-old male with facial disfigurement resulting
from a bear bite. Initial reports indicate that the patient
is doing well [124–126] (Table 1).
Hand and facial transplantation are now a clinical real-
ity. As has been the case in so many advances in medi-
cine, while these new treatments seem like an enormous
lead forward, in reality the individual components neces-
sary to accomplish these advancements have been around
and routinely used in clinical practice for some time. The
tissue transfer techniques used to transplant a hand or
facial tissue, while complex, are used routinely to reattach
amputated limbs and reconstruct complex facial defects.
The immunosuppression medications used to prevent
hand and facial tissue from rejecting have been used in
thousands of organ transplant recipients. All of the logis-
tics used to identify, select, harvest and transport the
donor tissue has been developed and is used routinely in
solid organ procurement. Then what is it that makes
hand and face transplantation seem like such an enor-
mous leap in medical advancement and what took the
medical community so long to actually take this step?
Perhaps, it is the fact that these treatments involve our
hands and our face, parts of our anatomy that play such
an important role in making us human.
The door has now been opened. As scientists and phy-
sicians it is now our duties to assure that hand and facial
transplantation move into the clinical research phase in a
thoughtful and well planned manner. To achieve this it is
essential that teams proposing to perform these new pro-
cedures have the necessary technical and immunological
expertise but more importantly that they develop and
adhere to well-defined ethical guidelines. These guidelines
should include open display and public and professional
discussion and evaluation. By openly sharing and discuss-
ing our successes as well as our failures we will assure
that this new and exciting medical frontier will reach
mainstream medicine as quickly as possible and thus
be made available to the many who suffer with these
disfiguring deformities.
The role of clinical scientists is to gather as much
knowledge as possible about new treatments from
research, clinical experience, professional and public dis-
cussion and with this inform the patient and his/her fam-
ily as best as is possible about the associated risks and
benefits. Armed with this information it is ultimately the
patient who must decide whether to be treated.
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